Trending news
Analyze
Pricing
Biogen

Biogen

Employees

Unknown size

Locations
HQ
Xconomy

Bio Roundup: Travel Ban, Pharma in DC, Biogen Splits, PCSK9 Wins

Xconomy

Insurer UHC Will Cover Biogen Spine Drug, But With Limits And Proof

Xconomy

Better Together, or Apart? Biogen, Bioverativ Head Down Separate Paths

Health Strategy Stock markets
Xconomy

Anthem Caps Coverage Of Biogen Spine Drug Despite Wide FDA Approval

Xconomy

Biogen to Pay $1.25B to Settle Forward Pharma Patent Suit on MS Drug

Xconomy

Families Fret As Insurers Mull Biogen's $750K Spine Disease Drug

Xconomy

Biogen Sets $750,000 Initial Price For First-Ever Spinal Atrophy Drug

Xconomy

Ionis, Biogen Make History With FDA Nod for Spine Disease Drug

Xconomy

New Data Show Biogen, Ionis Drug Might Help More With Rare Spine Disease

Xconomy

Biotech Roundup: Biogen Rumors, Theranos, Electro-Drugs & More

Xconomy

Biogen Buys Ionis Spine Disease Drug For $75M, Eyes FDA Filing

Xconomy

With Biogen at a Crossroads, CEO Scangos to Step Down

Strategy Health Stock markets
The Motley Fool

Better Buy: Biogen Inc. vs. Celgene Corporation

The Motley Fool

Why Biogen Inc. Is Down 22.5% In 2016

The Motley Fool

Is Biogen a Buy After its Clinical Failure?

Health Stock markets
The Motley Fool

Biotech Buzz: ASCO Winners and Losers and Biogen's Discouraging Failure

The Motley Fool

Better Buy: Anavex Life Sciences Corp. vs. Biogen

The Motley Fool

Why Biogen, LendingClub, and Valeant Pharmaceuticals Slumped Today

Stock markets Health
The Motley Fool

Why Biogen Inc's Shares Couldn't Find SYNERGY Today

The Motley Fool

Instant Analysis: Biogen's Anti-Lingo-1 Flunks Game-Changing Study In MS